Hau Giang Pharmaceutical (DHG) spends 458 billion VND to pay cash dividends, rate 35%

Recently, Hau Giang Pharmaceutical Joint Stock Company (DHG) has just announced a plan to pay cash dividends in 2022 with the rate increased from 30% according to the old plan to 35%. Correspondingly, each shareholder owning 01 share will receive 3,500 VND in dividends.

Currently, there are 130.75 million DHG shares in circulation on the market, so Hau Giang Pharmaceutical is expected to pay about 458 billion VND in dividends to existing shareholders. The last date to register to receive dividends will be March 17.

Hau Giang Pharmaceutical (DHG) pays cash dividend at 35% rate (Photo TL)

In the shareholder structure of Hau Giang Pharmaceutical, the most notable are Taisho Pharmaceutical Manufacturing Joint Stock Company and State Capital Investment Corporation (SCIC), both of which are major shareholders, owning 51.01% and 43.31% of the company's charter capital, respectively. With the above dividend payout ratio of Hau Giang Pharmaceutical, Taisho Pharmaceutical Manufacturing Joint Stock Company and SCIC are expected to receive VND233.43 billion and VND198.2 billion, respectively.

The increase in the dividend payout ratio of Hau Giang Pharmaceutical took place in the context of the relatively good business results of this unit in 2022. This is also quite understandable because 2022 recorded the growth of companies in the pharmaceutical industry, going against the downward trend of the stock market. The reason is considered by many experts to be because the demand for pharmaceutical products is still high after the pandemic, helping companies in this sector maintain growth momentum in the context of the global economic recession.

In the fourth quarter of 2022, Hau Giang Pharmaceutical achieved revenue of VND 1,330.3 billion, an increase of 21.7% over the same period last year. The high cost of goods sold caused gross profit to only reach VND 620.9 billion.

Revenue grew strongly but expenses during the period did not increase too much. Financial expenses increased slightly from VND25.1 billion to VND29.3 billion. Selling expenses increased from VND280.6 billion to VND287.6 billion. Business management expenses remained stable at VND73.4 billion. Net profit from business activities reached VND271.3 billion.

After deducting expenses and corporate income tax, Hau Giang Pharmaceutical's profit after corporate income tax was recorded at VND 236.2 billion, an increase of 38.5%.

Hau Giang Pharmaceutical's accumulated revenue in 2022 reached VND 4,676 billion, an increase of 16.8% compared to 2021. Profit after tax reached VND 988.5 billion, an increase of 27.2% over the same period.

Source: https://www.congluan.vn/duoc-hau-giang-dhg-phai-chi-458-ty-dong-chia-co-tuc-bang-tien-ty-le-35-post237572.html